Larimar Therapeutics released a peer‑reviewed study on April 30 2026 that demonstrates its lead candidate, nomlabofusp, raises frataxin levels in key tissues and that these increases are reflected in skin and buccal cells. The cross‑species data, covering mice, rats, and non‑human primates, show a strong correlation between frataxin elevations in organs such as heart and brain and the levels measured in peripheral tissues that can be sampled non‑invasively.
The study confirms that nomlabofusp delivers functional frataxin to the mitochondria of affected tissues, a critical step toward a disease‑modifying therapy for Friedreich’s ataxia. By establishing skin frataxin as a reasonably likely surrogate endpoint, the data support Larimar’s accelerated‑approval pathway and justify the company’s planned Biologics License Application (BLA) submission in June 2026.
"We are pleased to publish these findings that further reinforce nomlabofusp's mechanism of action and ability to restore FXN levels in clinically‑relevant tissues. Importantly, our studies show that after treatment, the increased levels in accessible tissues like skin and buccal cells reflect levels achieved in critical organs across mice, rats, and non‑human primates. Correlations in FXN levels between peripheral tissues has also been shown in patients with FA," said Carole Ben‑Maimon, MD, President and Chief Executive Officer. "The consistency seen across species further strengthens the translational relevance of our program, supports our planned accelerated approval pathway, and underpins our Biologics License Application (BLA) submission planned for June 2026. We are focused on continued execution across our near‑term registrational milestones and advancing nomlabofusp as the first potential disease‑modifying therapy for patients with FA."
Larimar’s financial backdrop remains a key context for investors. The company reported a net loss of $62.5 million ($0.73 per share) for Q4 2025, compared with a $28.8 million loss ($0.45 per share) in Q4 2024. For the full year 2025, the net loss was $165.7 million ($2.27 per share) versus $80.6 million ($1.32 per share) in 2024. Cash, cash equivalents, and marketable securities stood at $136.9 million as of December 31 2025, and proceeds from a February 2026 public offering extend the company’s runway into the second quarter of 2027.
"The consistency seen across species further strengthens the translational relevance of our program, supports our planned accelerated approval pathway, and underpins our Biologics License Application (BLA) submission planned for June 2026," added Ben‑Maimon. The study’s findings reinforce Larimar’s strategy to use skin frataxin as a surrogate endpoint, a key element that could accelerate regulatory approval and bring the first disease‑modifying therapy for Friedreich’s ataxia to patients.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.